Jesy Nelson, 34, said on Sunday that her newborn twins, Ocean Jade and Story Monroe Nelson-Foster, were diagnosed with spinal muscular atrophy type 1 (SMA1) after months of tests following a premature birth in May. She and her fiancé, Zion Foster, learned the girls face severe motor impairment and were told they are unlikely to walk or regain full neck strength, and that early treatment is critical. Nelson said the twins have already received treatment that can be life‑saving but stressed that rapid diagnosis matters because symptom onset determines outcomes. She posted the update after a long period in hospital and urged other parents to watch for early signs so treatment can begin as soon as possible.
Key takeaways
- Jesy Nelson revealed the twins’ SMA1 diagnosis in an Instagram video; the babies were born prematurely at 31 weeks on 15 May.
- The couple’s daughters are named Ocean Jade and Story Monroe Nelson‑Foster and underwent treatment soon after diagnosis.
- NHS statistics indicate about 70 children are born with SMA in the UK each year; without treatment, roughly 8% survive to age two.
- Three disease‑modifying SMA medicines have been available on the NHS since 2019; early, presymptomatic treatment can allow near‑normal development in some cases.
- NHS Scotland began a two‑year pilot adding SMA to its newborn screening in September (pilot start date: September last year), highlighting screening disparities across the UK.
- Nelson reported earlier pregnancy complications including twin‑to‑twin transfusion syndrome (TTTS) and an emergency procedure that led to a 10‑week hospital stay before delivery.
Background
Spinal muscular atrophy type 1 (SMA1) is the most severe and common early‑onset form of a genetic neuromuscular disorder. It causes progressive motor neuron loss, leading to profound muscle weakness, feeding difficulties, respiratory compromise and, historically, high early mortality if untreated. In recent years the treatment landscape changed: since 2019 several transformative therapies — including gene therapy and other disease‑modifying drugs — have been adopted by the NHS, improving survival and function when given early. Newborn screening is decisive because therapies are far more effective before symptoms appear; advocacy groups have pushed for SMA to be added to routine newborn screening panels across the UK.
Jesy Nelson’s case follows an already complex perinatal course: she reported twin‑to‑twin transfusion syndrome (TTTS), a serious complication affecting 10–15% of identical twins who share a placenta, and required emergency intervention. The babies were delivered prematurely at 31 weeks on 15 May, and the family says four months of repeated hospital assessments led to the SMA1 diagnosis. Parents of premature infants often receive reassurance that delayed milestones are due to prematurity, which can complicate and delay recognition of neuromuscular conditions.
Main event
Nelson posted an emotional Instagram video on Sunday describing the diagnosis and prognosis she and Foster were given after months of testing. Medical teams told them the twins are unlikely to walk and may not regain full neck control; the parents were urged to begin treatment promptly because untreated SMA1 often leads to life‑threatening complications in infancy. Nelson said the girls have received available treatment and that the interventions could be life‑saving if delivered quickly.
She described a sequence that began when her mother noticed limited leg movement and feeding struggles in the babies, signs which prompted hospital follow‑ups. Because the twins were premature, early assessments sometimes attributed low tone and slow movement to prematurity, delaying targeted tests. After specialist evaluation and genetic testing, clinicians confirmed SMA1 and started the twins on disease‑modifying therapy.
Nelson framed her public statement as both a personal update and a public service message: she urged parents and caregivers to look for signs such as pronounced floppiness, inability to hold up the head, a “frog‑leg” posture and rapid abdominal breathing. She emphasized that time is of the essence with SMA1 and that seeking immediate medical assessment can change outcomes.
Analysis & implications
The case highlights ongoing gaps in early detection: while effective treatments exist, outcomes hinge on delivering therapy before irreversible motor neuron loss. The UK does not yet have a uniform national newborn blood‑spot screening programme for SMA, and that creates disparities in which infants are identified presymptomatically. NHS Scotland’s pilot to add SMA to its screening in September last year shows one regional approach, but without UK‑wide coverage many infants will still be diagnosed only after symptoms appear.
Clinically, SMA1 historically carried a very poor prognosis; contemporary therapies — including gene replacement and antisense oligonucleotides — can dramatically alter that trajectory when given early. Published data and health‑service reports suggest infants treated pre‑symptomatically may reach motor milestones otherwise lost to the disease, but real‑world outcomes vary by age at treatment, baseline health and severity. For twins born prematurely, distinguishing prematurity‑related delay from neuromuscular disease is a diagnostic challenge that can delay access to therapy.
Policy implications are clear: adding SMA to routine newborn screening would increase presymptomatic detection and expand the window for optimal treatment. That change involves cost, logistics and ethical considerations (including consent and follow‑up), but many clinicians and charities argue the clinical benefits outweigh the hurdles. The broader social effect includes increased demand for long‑term supportive services, specialist physiotherapy and respiratory care for children with persistent motor impairment despite treatment.
Comparison & data
| Metric | Value (UK) |
|---|---|
| Estimated births with SMA per year | ~70 |
| Survival to age 2 without treatment | ~8% |
| NHS rollout of SMA therapies | From 2019 (three disease‑modifying medicines) |
| NHS Scotland screening | Added SMA to newborn pilot September (last year) |
These figures show the scale and urgency: although SMA is rare, the condition carries a high early mortality without treatment, and treatments introduced since 2019 have changed clinical expectations. The pilot in Scotland provides a test case for wider UK implementation; monitoring outcomes from the pilot will be important to inform a national policy decision.
Reactions & quotes
“We were told that they’re probably never going to be able to walk; they probably will never regain their neck strength.”
Jesy Nelson (Instagram)
Nelson’s statement framed the diagnosis and prognosis in stark terms and appealed directly to other parents to seek prompt medical assessment. Her public profile has amplified attention to SMA and newborn screening policy.
“Early detection is critical — treatment before symptoms appear offers the best chance of normal development.”
SMA UK (charity)
SMA UK has campaigned for inclusion of SMA in newborn blood‑spot screening and highlights that the UK lags other countries in routine screening coverage. Their guidance stresses rapid referral and access to therapy.
Unconfirmed
- Whether these specific twins will ever walk cannot be predicted with certainty; long‑term outcomes depend on age at treatment, individual response and complications from prematurity.
- The twins’ zygosity (whether they are identical) was not publicly confirmed; TTTS typically affects identical twins who share a placenta.
- Long‑term developmental and respiratory trajectories for twins treated after symptom onset remain variable and are still being characterized in real‑world registries.
Bottom line
Jesy Nelson’s disclosure brings a high‑profile, human story to the clinical and policy debate around SMA screening and early therapy. The case underscores how prematurity can mask early signs, delaying diagnosis at precisely the time when intervention is most effective. For clinicians and policymakers the message is pragmatic: expanding newborn screening and ensuring rapid referral pathways would increase the number of infants who can receive presymptomatic treatment.
For families, the immediate priority is clinical care and support: disease‑modifying therapies have changed potential outcomes, but individual prognosis is uncertain and long‑term needs can be substantial. Nelson’s plea to watch for floppy tone, feeding difficulties and abnormal leg positioning is consistent with clinical guidance — quick assessment and testing can materially change a child’s chances.
Sources
- The Guardian (media report summarising Jesy Nelson’s statement)
- NHS (official clinical information on SMA and outcomes)
- SMA UK (charity information and policy advocacy on newborn screening)